The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation
Academic Article
Publication Date:
2019
abstract:
DISCLOSURES: Labopin: Jazz Pharmaceuticals: Honoraria. Bug:Pfizer: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Honoraria; Hexal: Membership on an entity's Board of Directors or advisory committees; Gilead Sciences: Membership on an entity's Board of Directors or advisory committees, Other: Travel grants; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel grants; Sanofi: Other: travel grants; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene Neovii: Other: travel grant. Mohty:Jazz Pharmaceuticals: Honoraria, Research Funding.
Iris type:
1.1 Articolo in rivista
List of contributors:
Shouval, R.; Fein, J. A.; Labopin, M.; Bazarbachi, A.; Baron, F.; Bug, G.; Ciceri, F.; Corbacioglu, S.; Giebel, S.; Gilleece, M. H.; Montoto, S.; Peric, Z.; Polge, E.; Ruggeri, A.; Sanz, J.; Savani, B. N.; Schmid, C.; Spyridonidis, A.; Versluis, J.; Yakoub-Agha, I.; Mohty, M.; Nagler, A.
Published in: